Opendata, web and dolomites

URO-BEST

UROthelial carcinoma Biomarker based diagnostic tEST

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 URO-BEST project word cloud

Explore the words cloud of the URO-BEST project. It provides you a very rough idea of what is the project "URO-BEST" about.

perfom    81    nmp22    million    requiring    vs    licensing    tool    believe    unmet    40    yearly    94    gold    sensitivity    biomarker    japan    superior    validate    cancers    urine    invention    bladder    operate    validated    demonstrating    91    exists    genetic    diagnosis    tests    13    initial    discriminating    monitor    uro    detected    cystoscopies    period    relapse    surveillance    costly    cystoscopy    ongoing    rates    opportunity    multicenter    clinically    presenting    fina    200million    reduce    treat    costliest    controls    urovysion    70    cytology    usa    billion    international    biotech    diagnosed    expressed    patent    estimate    molecular    complications    1st    figures    diagnostic    assay    cancer    samples    stat    specificity    bta    12    survival    malignancies    near    protecting    global    380    signatures    genes    secure    worldwide    hence    patients    60    healhty    patient    filed    risk    frequent    healthcare    first    averaging    differentially       performance    525    urologists    transurethral    launch    providers    2013    invasive    freedom    combined    gt    standard    pct    market   

Project "URO-BEST" data sheet

The following table provides information about the project.

Coordinator
FINA BIOTECH S.L. 

Organization address
address: CAMINO DE LAS HUERTAS 2, EDIFICIO 1
city: POZUELO DE ALARCON
postcode: 28223
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.finabiotech.es/investigation/diagnostics/dx-bladder-cancer/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FINA BIOTECH S.L. ES (POZUELO DE ALARCON) coordinator 50˙000.00

Map

 Project objective

Bladder cancer is among the five most common malignancies worldwide: more than 380.000 new cases are diagnosed yearly. If detected early, 5-year survival is high (94%),but >70% of diagnosed patients will relapse within this period. The current gold standard diagnostic tool is combined cytology and cystoscopy which is costly and highly invasive requiring transurethral access and presenting the risk of important complications. Due to high relapse rates, surveillance requires frequent cystoscopies, averaging 13 controls per patient after initial diagnosis. Hence, bladder cancer is one of the costliest cancers to treat and monitor. Only in the USA, Europe and Japan, more than 4.5 million cystoscopies are conducted yearly, 40% for 1st diagnosis and 60% for surveillance, at a cost near to $2 billion to healthcare providers. Urologists believe that an opportunity exists to reduce the number of SURVEILLANCE cystoscopies with a reliable, cost-effective, robust, easy-to-perfom and non-invasive assay. URO-BEST addresses this unmet need. Based on signatures of 2, 5,10 and 12 differentially-expressed genes, this test has been clinically validated in a multicenter international study on 525 urine samples demonstrating 81% sensitivity and 91% specificity in discriminating cases vs. healhty patients for first diagnosis, figures comparable to that of the gold standard and superior to other existing molecular diagnostic products (Urovysion, NMP22, BTA Stat). We estimate the current market for bladder cancer biomarker based tests at greater than > $200million. Fina Biotech has filed European and PCT patent applications protecting the invention in 2013. Fina Biotech aims to clinically validate the diagnostic performance of the genetic signatures in patients under SURVEILLANCE for its launch to the market: advance ongoing discussions with potential partners for global licensing,increase urologists awareness and secure freedom to operate.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "URO-BEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "URO-BEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More